Last reviewed · How we verify
RSC-1255 Dose Escalation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
RSC-1255 Dose Escalation (RSC-1255 Dose Escalation) — RasCal Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSC-1255 Dose Escalation TARGET | RSC-1255 Dose Escalation | RasCal Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSC-1255 Dose Escalation CI watch — RSS
- RSC-1255 Dose Escalation CI watch — Atom
- RSC-1255 Dose Escalation CI watch — JSON
- RSC-1255 Dose Escalation alone — RSS
Cite this brief
Drug Landscape (2026). RSC-1255 Dose Escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/rsc-1255-dose-escalation. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab